VERAFEYEイメージングおよびナビゲーションシステムを用いたガイドカテーテルアブレーション手技の実現可能性に関する研究 (INSiGHT)
VERAFEYEイメージングおよびナビゲーションシステムを用いたガイド付きカテーテルアブレーション処置の実現可能性に関する研究
The objective of the study is to collect data on the usability and integration of the VERAFEYE Imaging and Guidance System in adult patients indicated to undergo a standard of care catheter-based ablation procedure for the treatment of Atrial Flutter (AFL), paroxysmal AF (PAF) or persistent AF (perAF).
Results from this study may be used to guide development and refinement the VERAFEYE Imaging and Guidance System capabilities.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Ivan Sikiric
- 電話番号:+385958934912
- メール:ivan.sikiric20@gmail.com
研究連絡先のバックアップ
- 名前:Ivan Aranza
- 電話番号:+385917947452
- メール:aranza.ivan@gmail.com
研究場所
-
-
-
Split、クロアチア、21000
- 募集
- Klinicki Bolnicki Centar (KBC) Split
-
主任研究者:
- Ante Anic
-
コンタクト:
- Ivan Sikiric
- 電話番号:+385958934912
- メール:ivan.sikiric20@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- IC1: Subject is at least 18 years of age at the time of consent
- IC2: Subject is scheduled to undergo a standard of care catheter-ablation procedure to treat AFL/AF, according to current international and local guidelines and per physician discretion
- IC3: Subject is able to understand and willing to provide written informed consent
- IC4: Subject is able and willing to complete all study assessments associated with this clinical study at an approved clinical study site
Exclusion Criteria:
- EC1: Subject where placement of VERAFEYE Imaging Catheter is technically not feasible per physician discretion
- EC2: Pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the procedure)
- EC3: Subject implanted with an active cardiac rhythm management device (e.g. pacemaker, CRT, ICD)
- EC4: Unrecovered/unresolved Adverse Events from any previous invasive procedure
- EC5: Any planned surgical or endovascular intervention within 30 days before or after the ablation procedure
- EC6: Life expectancy less than 12 months
- EC7: Current LA thrombus Note: Screening for LA thrombus is required to be performed within 48 hours prior to or during the index procedure. Method of screening per physician discretion. If an atrial thrombus is observed prior to or during the planned index procedure, the index procedure will not begin or will be terminated before accessing the left atrium, and no ablation will be performed. The index procedure for this subject may be rescheduled to be performed within 30 days post ICF signature, provided that the thrombus is no longer present.
- EC8: Subjects who are currently enrolled in another study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:デバイスの実現可能性
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Atrial Fibrillation and Atrial Flutter arm
Subjects entitled to undergo a catheter-based ablation treatment for typical atrial flutter and/or atrial fibrillation |
The VERAFEYE Imaging and Guidance System will be used during standard of care, catheter-based treatments for atrial flutter and/or atrial fibrillation. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
ADEs
時間枠:within 7 days of the index procedure
|
• Rate of device-related adverse events (ADEs) occurring within 7 days of the index procedure |
within 7 days of the index procedure
|
|
VERAFEYE Performance
時間枠:during procedure
|
• Ability of VERAFEYE Imaging and Guidance System to:
|
during procedure
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。